TABLE 2

Noncompartmental analysis of plasma DZP concentrations

FormulationDZPAVFAVF/APBAVF/APBAVF/APB
RouteIntravenousIntranasalIntranasalIntranasalIntranasal
Equiv. DZP dose (mg/kg) [dose level]1.00 [medium]1.00 [medium]0.500 [low]1.00 [medium]1.50 [high]
Tmax (min)0a10585
Cmax ± S.D. (ng/ml)441a108 ± 3071.5 ± 9.3388 ± 31355 ± 187
t1/2,z (min)32.933.4136b26.737.8
AUC0–15 min (min⋅ng/ml)1910 ± 70837 ± 28793 ± 543250 ± 1903850 ± 270
AUC0–90 min ± S.E. (min⋅ng/ml)5430 ± 1904230 ± 1202110 ± 1506080 ± 5109280 ± 470
F % ± S.E.n/a77.8 ± 3.577.8 ± 6.0112 ± 10114 ± 7
  • a Cmax reported for IV DZP is the concentration extrapolated to t = 0 min (i.e., the initial concentration C0) as calculated by WinNonlin noncompartmental analysis.

  • b Overestimation of terminal half-life t1/2,z owing to inherent variability of data below limit of quantification in terminal phase of low-dose group.